Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1 Estimated annual percentages of new

Advertisements

Additional file 2: Figure S1

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Model-Free Linkage Analysis with Covariates Confirms Linkage of Prostate Cancer to Chromosomes 1 and 4 Katrina A.B. Goddard, John S. Witte, Brian K.

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Prostate Cancer Nomograms: An Update

the SNP profile using 26 prostate cancer GWAS risk SNPs

Figure 5 Palliative-care-referral patterns

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Model-Free Linkage Analysis with Covariates Confirms Linkage of Prostate Cancer to Chromosomes 1 and 4 Katrina A.B. Goddard, John S. Witte, Brian K.

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Calibration plots for the clinical GDRS in the EPIC-Potsdam study (A) and the GNHIES98 cohort (B). Predicted risks were determined using score points,

Figure 3 Determination of the primary site

Figure 4 Algorithm for when to determine PTEN

External model validation of binary clinical risk prediction models in cardiovascular and thoracic surgery Graeme L. Hickey, PhD, Eugene H. Blackstone,

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gene-expression quantification methods

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.80 Figure 1 Calibration plot of the STHLM3 model for predicting high-risk prostate cancer Figure 1 | Calibration plot of the STHLM3 model for predicting high-risk prostate cancer. The graph shows the calibration of the model — that is, the agreement between the predicted and observed risk of high-risk prostate cancer (Gleason score ≥7) — based on the results from the 5,344 biopsies performed in the STHLM3 validation cohort. The red line indicates perfect correspondence between predicted and observed risk (perfect calibration) and the black line shows the calibration of the STHLM3 model. The orange shaded area indicates the 95% confidence interval, and the tick lines above the x-axis shows deciles of the risk distribution, each representing one tenth of the population. The graph was produced using the R language and the gbm package10,11. Eklund, M. et al. (2016) The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.80